20730-58-9

Basic information

• Product Name: 4-(2-Methoxyphenyl)heptane-3,5-dione
• Synonyms: 4-(2-Methoxyphenyl)heptane-3,5-dione;2-(2-Methoxyphenoxy)propanedioic acid 1,3-diethyl ester;Diethyl (2-methoxyphenoxy)malonate;Diethyl 2-(2-methoxyphenoxy)malonate;Diethyl (2-Methoxyphenoxy)propanedioate;diethyl 2-(2-methoxyphenoxy)propanedioate
• CAS NO: 20730-58-9
• Molecular Formula: C₁₄H₁₈O₆
• Molecular Weight: 234.29092
• Mol File: 20730-58-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 351.331oC at 760 mmHg
• Flash Point: 151.845oC
• Appearance: /
• Density: 1.157
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.493
• PKA: 12.22±0.59(Predicted)
• CAS DataBase Reference: 4-(2-Methoxyphenyl)heptane-3,5-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-Methoxyphenyl)heptane-3,5-dione(20730-58-9)
• EPA Substance Registry System: 4-(2-Methoxyphenyl)heptane-3,5-dione(20730-58-9)

Safety Data

• Hazardous Substances Data: 20730-58-9(Hazardous Substances Data)

Usage

General Description

4-(2-Methoxyphenyl)heptane-3,5-dione, also known as piperonyl butoxide, is a synergist commonly used in insecticides to enhance the effectiveness of the active ingredients. It works by inhibiting the activity of enzymes in insects that break down the insecticides, allowing the active ingredients to remain effective for longer periods of time. Piperonyl butoxide is a colorless to light yellow liquid with a slightly sweet odor and is considered to have low acute toxicity to humans. It is primarily used in combination with pyrethroid insecticides for agricultural and household pest control, as well as mosquito control. However, prolonged exposure to piperonyl butoxide may have potential health effects and it is important to handle and use it according to the manufacturer's instructions.

InChI:InChI=1/C14H18O6/c1-4-18-13(15)12(14(16)19-5-2)20-11-9-7-6-8-10(11)17-3/h6-9,12H,4-5H2,1-3H3

Upstream product

• 13052-77-2 sodium 2-methoxyphenolate 
• 14064-10-9 diethyl 2-chloromalonate 
• 90-05-1 2-methoxy-phenol 
• 105-53-3 diethyl malonate 
• 685-87-0 Diethyl 2-bromomalonate 

Downstream Products

• 14007-09-1 2-(2-methoxyphenoxy)-1,3-propanediol 
• 329923-15-1 4,6-dihydroxy-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidine 
• 329924-93-8 5-(o-methoxyphenoxy)-4,6-dihydroxy-2-methyl-pyrimidine 
• 184779-24-6 4,6-dihydroxy-5-(2-methoxyphenoxy)-2-methylthiopyrimidine 
• 150728-08-8 5-(o-methoxyphenoxy)-4,6-dihydroxy-2-(pyridin-4-yl)-pyrimidine 
• 329924-46-1 5-(o-methoxyphenoxy)-4,6-dihydroxy-2-(N-morpholino)-pyrimidine 
• 150727-22-3 5-(o-methoxyphenoxy)-4,6-dihydroxy-pyrimidine 
• 473537-03-0 5-(2-methoxy-phenoxy)-2-pyrazin-2-yl-pyrimidine-4,6-diol 
• 659725-69-6 5-(2-methoxy-phenoxy)-2-(2-methyl-pyridin-4-yl)-pyrimidine-4,6-diol 
• 184779-18-8 5-(2-methoxyphenoxy)-pyrimidine-2,4,6-trione 
• 150728-12-4 5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl) pyrimidine-4,6(1H, 5H)-dione 
• 147536-97-8 bosentan 
• 150727-06-3 4-tert-butyl-N-(6-chloro-5-(2-methoxyphenoxy)2,2'-bipyrimidin-4-yl)benzene sulfonamide 

Relevant articles and documents

2-methoxyphenoxy pyrimidine antitumor compound as well as preparation method and application thereof

The invention belongs to the technical field of medicines, relates to a compound with anti-tumor activity and a specific chemical structure, and particularly relates to a 2-methoxyphenoxy pyrimidine compound as well as a preparation method and application thereof. The structural general formula of the 2-methoxyphenoxy pyrimidine compound is shown in the specification, wherein an R group is a hydrogen atom, or a 2-position monosubstituted fluorine atom, or 3-position and 4-position monosubstituted methyl, methoxy, fluorine atom, chlorine atom, bromine atom and iodine atom. Experimental research shows that the prepared 2-methoxyphenoxy pyrimidine compound shows a good result in an in-vitro anti-tumor activity test, has certain inhibitory activity on human malignant melanoma A375 cells, can be used for preparing anti-tumor drugs, and opens up a new way for developing new anti-tumor drugs. The preparation method provided by the invention is simple and feasible, relatively high in yield and easy for large-scale production.

Novel Allosteric Inhibitors of Deoxyhypusine Synthase against Malignant Melanoma: Design, Synthesis, and Biological Evaluation

Based on the novel allosteric site of deoxyhypusine synthase (DHPS), two series of 30 novel 5-(2-methoxyphenoxy)-2-phenylpyrimidin-4-amine derivatives as DHPS inhibitors were designed and synthesized. Among them, compound8m, with the best DHPS inhibitory potency (IC50= 0.014 μM), exhibited excellent inhibition against melanoma cells, which was superior to that of GC7. Besides, molecular docking and molecular dynamics (MD) simulations further proved that compound8mwas tightly bound to the allosteric site of DHPS. Flow cytometric analysis and enzyme-linked immunosorbent assay (ELISA) showed that compound8mcould inhibit the intracellular reactive oxygen species (ROS) level. Furthermore, by western blot analysis, compound8meffectively activated caspase 3 and decreased the expressions of GP-100, tyrosinase, eIF5A2, MMP2, and MMP9. Moreover, both Transwell analysis and wound healing analysis showed that compound8mcould inhibit the invasion and migration of melanoma cells. In thein vivostudy, the tumor xenograft model showed that compound8meffectively inhibited melanoma development with low toxicity.

Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals

Methods of treating chronic arthritis and osteoporosis which utilize both known and novel compounds which would fall under the general formula:(HO)p--A--[--OS(O) 2 NR 1 R 2 ] zwherein A encompasses a wide range of values including but not limited to aryl, loweralkyl, cycloalkyl, and carbohydrates including sucrose and fructose; p is equal to the number of unreacted hydroxy groups contained on the molecule and may be zero; z is the number of --OS(O) 2 NR 1 R 2 groups and is always at least one; R 1 and R 2 are selected from hydrogen, loweralkyl, carboxy and the like; a novel process for preparing the compounds is provided wherein an appropriate sulfamic acid aryl ester is reacted with a hydroxy substituted A radical which may or may not contain thereon protected carboxyl, amino or hydroxy substituents, in an aprotic solvent containing a tertiary amine base. Pharmaceutical compositions for the treatment of chronic arthritis and osteoporosis are also provided.